AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02423629 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Agili-C™ implantation procedure
Description: Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
Study NCT00251121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini-invasive electrophysiological study
Description: Transvenous pacing in right heart atrium
Study NCT00251121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Description: Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
Study NCT01252277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza™
Description: 4 capsules daily for 6 months
Study NCT02965937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Story-centred care intervention program
Description: Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks.
Study NCT02965937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health consultation control condition
Description: The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
Study NCT00549432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TALENT Enhanced LPS Endoluminal Stent-Graft System
Description: roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
Study NCT00612092 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spiral image acquisition
Description: standard spiral scan protocol
Study NCT00612092 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: sequential image acquisition
Description: sequential CT scan protocol
Study NCT00534456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
Study NCT00534456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
Study NCT01756430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol SR 32mg, QD
Description: * Carvedilol SR 32mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.
Study NCT03053869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzodiazepine - limited use strategy
Description: 1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia.
Study NCT03053869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzodiazepine - Ad libitum strategy
Description: 1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy).
Study NCT03238118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention bias modification training
Description: Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.
Study NCT03238118 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Training
Description: Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.
Study NCT03238118 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
Study NCT03238118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
Study NCT03189966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversalis fascia plane block
Description: With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
Study NCT03189966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadratus lumborum block
Description: The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
Study NCT01194622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine, Fluticasone
Description: TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
Study NCT01194622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone mono
Description: REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
Study NCT01194622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
Study NCT02519569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy
Description: The intervention consists of ten writing assignments
Study NCT01224444 — intervention group
Intervention type: OTHER
Intervention: standard polypectomy snare
Description: Electrocautery snare resection of sessile colonic polyps
Study NCT04029571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM-FMD
Description: Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks.
Study NCT04029571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FMD
Description: A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD.
Study NCT01442805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Participants are exposed to the feared situation (flying) through the virtual reality technology
Study NCT01442805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy through Imagination
Description: Participants are exposed to the feared situation (flying) through exposure technique of imagination.
Study NCT03083184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
Study NCT00655785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1-1084, VEGFR2-169
Description: One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
Study NCT00655785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
Study NCT04209322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed Radiofrequency
Description: Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging
Study NCT04209322 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Epidural Steroid Injection
Description: Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
Study NCT03083184 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: enoxaparin
Description: An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
Study NCT01756430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol SR 64mg, QD
Description: * Carvedilol SR 64mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.
Study NCT01756430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol IR 25mg, QD
Description: * Carvedilol IR 25mg QD for 4 weeks~* With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks.
Study NCT01756430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol IR 25mg, BID
Description: * Carvedilol IR 25mg BID for 4 weeks~* With the others investigation product placebo 2 capsules QD for 4 weeks.
Study NCT02441725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1-minute sit-to-stand test
Description: Validation of the 1-minute sit-to-stand test in a COPD patient population
Study NCT01439178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Avastin injection
Description: Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
Study NCT01439178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Avastin injection
Description: Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
Study NCT01756443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine/adrenaline and 0.5% bupivacaine
Study NCT01756443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine/adrenaline and 0.5% bupivacaine
Study NCT02196480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-TNF
Description: Anti-tumor necrosis factor therapy
Study NCT01445704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05.
Study NCT02182271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 ZW - single rising dose
Study NCT02182271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04386876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet
Description: Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
Study NCT01445704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
Study NCT05600673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution
Description: Topical Bimatoprost 0.03% solution
Study NCT05600673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser
Description: CO2 fractional laser treatment
Study NCT05600673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 fractional laser
Description: CO2 fractional laser treatment
Study NCT04233424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-PLEX
Description: D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
Study NCT04233424 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Description: prophylactic, pre-operation per institution guidelines
Study NCT02796053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB08
Description: The TAB08 will be administered intravenously, by infusion.
Study NCT02796053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo to TAB08 will be administered intravenously, by infusion.
Study NCT01467440 — intervention group
Intervention type: DEVICE
Intervention: Selective Laser Trabeculoplasty
Description: trabeculoplasty with an SLT-Laser to reduce intraocular pressure
Study NCT03928301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wholetones Music
Description: Participants listened to the Wholetones music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
Study NCT03928301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classical Music
Description: Participants listened to the classical music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
Study NCT01957397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 1
Description: Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
Study NCT01957397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 2
Description: Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
Study NCT01957397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 3
Description: Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
Study NCT03687840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: gait analysis
Description: Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
Study NCT03746392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jumpstart Intervention
Description: The intervention has 4 steps: use electronic medical record (EHR) to identify seriously ill, hospitalized patients with no documentation of a goals-of-care (GOC) discussion during their current admission; the enrolled patient or his/her surrogate completes a survey assessing preferences for discussions about GOC, barriers to having such discussions, and current GOC which is used to create a Jumpstart form designed to prompt and guide a GOC discussion between the patient or surrogate and the clinicians caring for the patient; use natural language processing/machine learning (NLP/ML) approach to identify GOC discussions or advance directives in the EHR that occurred prior to admission and include this information on the Jumpstart form; and, deliver the Jumpstart form to the primary clinician team. The patient or surrogate is also provided with a version of the form.
Study NCT04007198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EQ001
Description: Itolizumab \[Bmab 600\]
Study NCT04007198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EQ001 Placebo
Description: EQ001 Placebo
Study NCT03251170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive :1 mg/Kg ketamine for induction of anesthesia
Study NCT03251170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
Study NCT03251170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients will receive 0.05 mg/Kg midazolam
Study NCT03251170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients will receive 0.05 mg/Kg midazolam
Study NCT03825718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC007F
Description: GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.
Study NCT02756130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: Given IV
Study NCT02756130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02756130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02756130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00741507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Never drinking of alcohol
Study NCT00741507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)
Study NCT00741507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)
Study NCT00741507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)
Study NCT00741507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)
Study NCT02910804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BBN-IRDye800CW
Study NCT02910804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/NIRF